BEVERLY, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced that the Company’s President, Daryl Rebeck, will present at two upcoming investor conferences that are taking place in September 2018.

Following LexaGene’s entrance into the beta stage of product development for the Company’s flagship pathogen detection system in July, Mr. Rebeck will speak at the Liolios 7th Annual Gateway Conference, taking place on Sept. 5–6 at the Four Seasons Hotel in San Francisco. The Gateway Conference is an invite-only conference that was created to bring together the most compelling companies with the nation's top institutional investors and analysts. Mr. Rebeck presents on Sept 5 at 2:30pm in Yerba Buena B.

In addition, LexaGene has been selected to present at the third annual MicroCap Leadership Summit, hosted by MicroCapClub, on September 28, 2018 at the Westin Chicago Northwest Hotel in Itasca, IL. This two-day event brings together some of the most compelling microcap companies to present, and provides an opportunity to network with many of the best microcap investors in North America.

Mr. Rebeck states, “This is an excellent opportunity for the Company to present to retail and institutional investors about our advancements during the beta phase of product development.”

To view the LexaGene investor presentation, please visit the Investors page of the Company website here. To be added to the LexaGene email distribution list, please subscribe on the Company website here.

About LexaGene Holdings Inc.

LexaGene is a biotechnology company developing the very first fully automated pathogen detection platform that is open-access, the LX6. The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The instrument is expected to offer excellent sensitivity, specificity, and breadth of pathogen detection. The instrument will be able to process six samples at a time, in an on-demand fashion, returning results in about 1 hour. The company expects to sell its technology in the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com ). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contacts Caitlin Kasunich / Amy Singh KCSA Strategic Communications 212.896.1241 / 212.896.1207 ckasunich@kcsa.com / asingh@kcsa.com

Investor Relations Jay AdelaarVice President of Capital Markets, LexaGene800.215.1824 ext 207 jadelaar@lexagene.com